You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • P194 Epivin: a phase II double-blind randomised control trial investigating the use of epigallocatechin-3-gallate (veregen®, catephen®) vs placebo in the treatment of usual-typed vulval intraepithelial neoplasia

Article info

Article menu
Download PDFPDF
Poster exhibition Day 2
P194 Epivin: a phase II double-blind randomised control trial investigating the use of epigallocatechin-3-gallate (veregen®, catephen®) vs placebo in the treatment of usual-typed vulval intraepithelial neoplasia

Authors

Citation

Yap J, Slade D, Fox R, et al
P194 Epivin: a phase II double-blind randomised control trial investigating the use of epigallocatechin-3-gallate (veregen®, catephen®) vs placebo in the treatment of usual-typed vulval intraepithelial neoplasia
International Journal of Gynecologic Cancer 2019;29:A173.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.